Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01851694 · ClinicalTrials.gov registry record · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
A NA study of Cystic Fibrosis and Pancreatic Insufficiency, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT01851694 is a NA study of Cystic Fibrosis and Pancreatic Insufficiency that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 45 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01851694, a NA study of Cystic Fibrosis and Pancreatic Insufficiency, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has many features similar to both T1D and T2D, patients with CF may not have the same symptoms as either T1D or T2D patients. Currently, there is little understanding of CFRD and the best options for treatment remain unclear. The purpose of this research study is to examine and understand the various mechanisms that contribute to CFRD and gain a better understanding of potential means to treat CFRD. In particular, we plan to study the effects of incretin hormones that can enhance insulin production in CF patients. Enrollment is complete for the protocol as initially written. In order to further study the role of the incretin hormone on Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function , we have received approval to extend our investigation to include the following study groups: * Cystic Fibrosis participants with normal glucose tolerance * Non-Cystic Fibrosis controls
Conditions Studied
Interventions
- DRUG GLP-1
- DRUG GIP
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia and University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-05 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01851694
The ClinicalTrials.gov registry entry for NCT01851694 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (75% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which GLP-1 is the first listed.
NCT01851694 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01851694 about?
NCT01851694 is a clinical study titled "Beta-cell Response to Incretin Hormones in Cystic Fibrosis". In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Ins...
What is the current status of trial NCT01851694?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2013-05. Estimated completion is 2026-12.
What conditions does trial NCT01851694 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Pancreatic Insufficiency.
What interventions are being tested in trial NCT01851694?
The interventions under investigation include: GLP-1 (DRUG), GIP (DRUG).
Who is sponsoring clinical trial NCT01851694?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01851694 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise in Child Health
RECRUITING · NA
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
FEED-Cystic Fibrosis (FEED-CF)
RECRUITING · NA
-
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
RECRUITING · NA
-
Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)
RECRUITING · NA
-
Lung Transplant READY CF 2: CARING CF Ancillary RCT
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.